Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of ALTU-135 in cystic fibrosis-related exocrine pancreatic insufficiency
2007-000178-21Phase 3Completed
- Sponsor
- Altus Pharmaceuticals Inc.
- Start
- Sep 2007
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of liprotamase in exocrine pancreatic insufficiency (EPI) and cystic fibrosis (CF), sponsored by Altus Pharmaceuticals Inc. Primary endpoint: Long-term safety and tolerability of ALTU-135. Started Sep 2007; status: completed.
02
Drugs
liprotamase
03
Conditions
exocrine pancreatic insufficiency (EPI)cystic fibrosis (CF)
Beyond the preview
Go deeper on 2007-000178-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000178-21.